The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.

about

Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?

P2860

Q30239856-7F128ECE-8FC5-4E44-9D82-207418741DA6

P2860

The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q40676691

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The effectiveness of a real li ...... litis and psoriatic arthritis.

@en

type

Item

label

The effectiveness of a real li ...... litis and psoriatic arthritis.

@en

prefLabel

The effectiveness of a real li ...... litis and psoriatic arthritis.

@en

P1476

The effectiveness of a real li ...... litis and psoriatic arthritis.

@en

P2093

Brian Davidson

http://www.w3.org/2001/XMLSchema#string

Chris Holroyd

http://www.w3.org/2001/XMLSchema#string

Christopher J Edwards

http://www.w3.org/2001/XMLSchema#string

Cyrus Cooper

http://www.w3.org/2001/XMLSchema#string

Elaine Dennison

http://www.w3.org/2001/XMLSchema#string

Ray Armstrong

http://www.w3.org/2001/XMLSchema#string

Warren Fong

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study.

Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.

Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up.

P304

1837-1842

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEW269

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas C Harvey

P577

2016-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27354684

http://www.w3.org/2001/XMLSchema#string

P921

TNF

The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.

about

P2860

P2860

The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921